Compass Pathways(NASDAQ) CMPS

COMPASS Pathways plc helps people who suffer from severe mental health conditions. The company creates new treatments for patients who do not respond to standard care. These therapies use psilocybin, a compound found in certain mushrooms, to help the brain heal.

Clinical Programs and Candidates

• COMP360 Psilocybin Treatment: Investigational therapy using pharmaceutical-grade psilocybin; currently in late-stage Phase 3 clinical trials for treatment-resistant depression.
• TRD Program: Development track for depression patients who do not respond to standard antidepressants; currently undergoing two pivotal Phase 3 trials.
• PTSD Program: Clinical effort investigating treatment for post-traumatic stress disorder; cleared to begin Phase 2b/3 trials as of January 2026.

Recent Milestones and Funding

• Received Breakthrough Therapy designation from the FDA for COMP360 in 2018.
• Achieved primary endpoints in two Phase 3 pivotal trials for depression by early 2026.
• Initiated a rolling review process with the FDA for a New Drug Application in early 2026.
• Raised $140.5 million in net proceeds through a public offering in February 2026.

New Approaches to Psychiatric Care

Compass focuses on rapid-onset treatments that offer long-lasting relief with only infrequent dosing. The company has developed a proprietary form of crystalline psilocybin optimized for medical stability and use in clinical settings.

Financial Highlights and Status

• Market capitalization reached $1.9 billion in Q2 2026, up 631.1% year over year.
• Net loss was $162.6 million for the six months ended June 30, 2026, compared to $56.3 million in 2025.
• Cash and cash equivalents totaled $433.3 million as of June 30, 2026.
• Research and development expenses were $55.7 million during the first half of 2026.
• Accumulated deficit grew to $985.2 million as of June 30, 2026.

Path to Commercialization

Compass has transitioned from early research to late-stage clinical trials for its lead psilocybin candidate. The company is currently building the infrastructure needed to launch its first commercial product if regulatory approval is granted.